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Abstract
Background: Despite years of interest in the anti-cancerous effects of cardiac glycosides (CGs), and numerous studies in
vitro and in animals, it has not yet been possible to utilize this potential clinically. Reports have demonstrated promising in
vitro effects on different targets as well as a possible therapeutic index/selectivity in vitro and in experimental animals.
Recently, however, general inhibition of protein synthesis was suggested as the main mechanism of the anti-cancerous
effects of CGs. In addition, evidence of species differences of a magnitude sufficient to explain the results of many studies
called for reconsideration of earlier results.
Principal Findings: In this report we identified primary B-precursor and T-ALL cells as being particularly susceptible to the
cytotoxic effects of CGs. Digitoxin appeared most potent and IC50 values for several patient samples were at concentrations
that may be achieved in the clinic. Significant protein synthesis inhibition at concentrations corresponding to IC50 was
demonstrated in colorectal tumour cell lines moderately resistant to the cytotoxic effects of digoxin and digitoxin, but not in
highly sensitive leukaemia cell lines.
Conclusion: It is suggested that further investigation regarding CGs may be focused on diagnoses like T- and B-precursor
ALL.
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Introduction
Cardiac glycosides (CGs) are a group of plant-derived
compounds that have been used for many years in traditional
medicine and that are currently used in treatment of cardiac
failure and atrial fibrillation. In parallel to this use, CGs have also
received attention as potential drugs in the treatment of various
malignant diseases. Epidemiological observations suggest that
patients on digitalis medication diagnosed with breast cancer in
general present with lower proliferating tumours of smaller size,
and subsequently better prognosis than control groups [1,2,3,4],
and that a high concentration of digitoxin could reduce the risk of
developing leukaemia, lymphoma or urogenital cancer [5]. In vitro
experiments have shown that CGs can induce cell death in several
cell lines derived from solid cancers [6,7] as well as in leukaemic
cell lines [8,9,10,11].
In the myocardium, CGs bind reversibly to the a-subunit of
Na
+/K
+ ATPase, leading to a rise in intracellular sodium levels,
which then results in an increase of calcium ions in the myocytes.
The mechanism of the cytotoxic effects of CGs on tumour cells has
been a subject of many studies but it largely remains unanswered.
Binding to Na
+/K
+ ATPase is not only a way of regulating ion
pumps in the cell membrane but it can also activate several
signalling pathways in the cell. For example, calcium-dependent
activation of caspases and other hydrolytic enzymes [7,12,13],
generation of reactive oxygen species (ROS) [14], topoisomerase
inhibition [15], interference with signal transduction pathways
(e.g. Src-mediated phosphorylation of epidermal growth factor
receptor (EGFR) and induction of the cell cycle inhibitor p21
Cip1
[16] have all been associated with the anti-tumour effects of CGs.
Digoxin-Like Immunoreactive Factors (DLIFs, also termed
Digitalis-Like Compounds (DLCs)) are endogenous steroids
identified in human tissues and they are identical or similar to
plant and amphibian steroids. The DLIFs are believed to be
synthesized in the adrenal gland, and to affect ion transport via
Na
+/K
+ ATPase. Binding of these compounds to Na
+/K
+ ATPase
may activate changes in intracellular Ca
2+ homeostasis and in
specific gene expression [17], and may be associated with the
development of malignancies [18]. Interestingly, DLIFs selectively
induce apoptosis in a human acute T-cell lymphoblastic leukaemia
cell line but not in the myelogenous leukaemia cell line K-562 or
healthy human peripheral blood mononuclear cells (PBMCs) [19].
Despite years of interest in these effects and numerous studies in
vitro and in animals, it has not yet been possible to utilize the anti-
cancerous potential of CGs clinically. Recently, a very discourag-
ing report on this issue was published, suggesting general
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cancerous effects of CGs, and species differences of a magnitude
sufficient to explain the results of most preclinical studies [20].
During a routine screening programme carried out in vitro we
observed that some samples of acute leukaemia were extremely
sensitive to the cytotoxic effects of digitoxin, thus prompting
further investigation. Hence this study was undertaken to
categorize the activity of some CGs in primary cultures from
patients with various leukaemic diagnoses, and to determine if
general protein inhibition is the dominant mechanism of action,
and if a therapeutic index in vitro exists.
Materials and Methods
Patient Samples and Cell Lines
Cryopreserved cells from bone marrow or peripheral blood
from adult patients with B-precursor or T-acute lymphoblastic
leukaemia (ALL), acute myeloid leukaemia (AML) and chronic
lymphocytic leukaemia (CLL) were used in the study. Peripheral
blood mononuclear cells (PBMCs) from healthy donors were used
as controls.
Informed consent was obtained from all patients (verbal until
2006 and written thereafter) to save diagnostic samples in a
biobank to be used for scientific research. The informed consent
was verbal until 2006 (in accordance with the approval from the
Ethics Committee) and the Ethics Committee did not demand that
the consent should be documented at this time (until 2006). Since
2006 written consent has been obtained. Sampling for drug
sensitivity testing was approved by the local Ethics Committee in
Uppsala (Regionala etikpro ¨vningsna ¨mnden i Uppsala, Sweden,
approval number Dnr 21/93). The samples from the biobank used
in the study were coded but labelled with diagnosis.
The T-lymphoblast-like cell line CEM/VBL100 (CCRF-CEM)
[21] was kindly donated by professor W.T. Beck, St. Jude’s
Children’s Research Hospital, USA and the B-precursor Phila-
delphia-positive cell line SUP-B15 [22] was obtained from
Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH, Germany. The cells were grown in complete medium
(CCRF-CEM in RPMI 1640 and SUP-B15 in McCoy’s 5A) and
split twice weekly. The colorectal adenocarcinoma cell lines
Hct116, HT29 and CC20 were used as comparator cell lines as
regards effects on protein synthesis.
Chemicals and Reagents
The CGs digitoxin, digoxin and ouabain were purchased from
Sigma (Sigma-Aldrich, Stockholm, Sweden). The compounds
were dissolved in DMSO and further dilution was in PBS. The
drugs were tested at five concentrations (ten-fold dilution steps)
ranging from 100 mM to 0.01 mMo r1 0mM to 0.001 mM. The
maximum concentration of DMSO did not exceed 1% in the cell
cultures. The serially diluted stock solutions were transferred to
384-well microtitre plates (NUNC, Roskilde, Denmark) and
control wells were filled with PBS only (5 ml/well).
Measurement of Cytotoxic Activity
The cytotoxic activity of the CGs was measured by using a
fluorometric microculture cytotoxicity assay (FMCA) as previously
described [23,24]. The method is based on measurement of the
fluorescence derived by hydrolysis of fluorescein diacetate (FDA)
to fluorescein by cells with intact plasma membranes. Cell
suspensions were seeded into drug-prepared 384-well microtitre
plates. Wells with medium only served as blanks. The plates were
incubated at 37uC for 72 hours; thereafter FMCAs were
performed using an automated Optimized Robot for Chemical
Analysis (Orca; Beckman Coulter Fullerton, CA) programmed
through SAMI software (Beckman Coulter). The plates were
washed in physiological buffer and FDA added. After 50 min of
incubation at 37uC, fluorescence was measured at 485/520 nm
using a Fluostar Optima microplate reader (BMG Technologies,
Germany). The fluorescence measured is proportional to the
number of living cells in each well.
Because a 30–40 nM plasma concentration of digitoxin can be
maintained in patients for many days, additional experiments with
extended incubation time (6 days) was performed. Leukaemic
patient cells and the CCRF-CEM cell line was treated with
therapeutically achievable concentrations (10, 30 and 50 nM) of
digitoxin in 96-well microtiter plates. To simulate a situation with
daily dosing, 50% of the medium (including drug to treated cells)
was exchanged every day.
Quality control was evaluated for each test by demanding a
signal/blank ratio of .10 and a coefficient of variation in controls
and blanks of ,30%. The proportion of leukaemic cells in primary
Figure 1. Cytotoxic IC50 values. Cytotoxic IC50 values (mM) for
digitoxin (A) and oubain (B) in primary cultures of human leukaemia
cells (T-ALL, B-precursor ALL, AML and CLL) and PBMCs.
doi:10.1371/journal.pone.0015718.g001
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morphologically.
Measurements of protein and nucleic acid synthesis
inhibition
Effects on DNA and protein synthesis were monitored in
Cytostar-TH plates (available in the ‘‘In Situ mRNA Cytostar-TH
assay’’ kit, Amersham International, Buckinghamshire, UK) using
14C-labelled thymidine and leucine. A Cytostar-TH plate is a 96-
well microtitre plate with scintillants molded into the transparent
polystyrene bottom. When labelled substrate is absorbed into the
intracellular compartment of the cells at the bottom of the wells,
the radioisotope is brought into proximity with the scintillant,
thereby generating a detectable signal. Free radiolabelled substrate
in the supernatant is unable to stimulate the scintillant [25,26].
CCRF-CEM and SUP-B15 cells were suspended in fresh
medium containing
14C-thymidine (111 nCi/ml; for DNA exper-
iments) or
14C-leucine (222 nCi/ml; for protein experiments),
yielding final radioactivity in the wells of 20 and 40 nCi,
respectively. Cell suspension (50610
3 cells in 180 ml) was added
to each well; blank wells had isotope-containing medium only.
Drugs (digoxin and digitoxin at final concentrations of 10 mMt o
1 nM) and PBS in test and control wells were added in duplicate
(20 ml per well) 2 hours after cell seeding, when the measured
radioactivity in cell-containing wells was at least double compared
with blank wells. Radioactivity was measured with a computer-
controlled Wallac 1450 MicroBetaH trilux liquid scintillation
counter (Wallac OY., Turku, Finland) immediately after addition
of the cell suspension and at different time points up to 72 hours.
Between measurements, the plates were stored in an incubator at
37uC. During measurement, the plates were covered with a plate
sealer to inhibit microbiological contamination.
Results
The cytotoxic activities of digitoxin and ouabain were studied in
primary leukaemic cells: T-ALL (n= digitoxin 4; ouabain 7), B-
precursor ALL (n=10; 6), AML (n=11;11), CLL (n=9; 6) and
PBMCs (n=4; 8) using the FMCA. Similar tests on the activity of
digoxin, digitoxin and ouabain were performed in the leukaemia
cell lines CCRF-CEM and SUP-B15. All tests were carried out in
triplicate.
The primary T- and B-precursor ALL cells were significantly
more sensitive to digitoxin than CLL cells (Mann–Whitney test,
p=0.02 and 0.006 respectively) and PBMCs (p=0.02 and 0.005
respectively) (Figure 1A). The median IC50 value regarding
digitoxin was 0.07 mM for T-ALL and 0.06 mM for B-precursor
ALL cells, compared with 0.44 mM for PBMCs (Table 1). For the
AML cells a scattered distribution regarding IC50 values was
observed. As regards ouabain, the IC50 value was significantly lower
(Mann–Whitney test, p=0.02) for the T-ALL cells than for CLL
cells but otherwise no significant differences were observed in the
different leukaemic cells or the PBMCs (Figure 1B and Table 1).
At 0.1 mM the B-precursor and T-ALL cells were significantly
more sensitive to digitoxin than the CLL cells and PBMCs (Mann–
Whitney test, B-precursor ALL vs. CLL p=0.0003, B-precursor
ALL vs. PBMCs p=0.002, T-ALL vs. CLL, p=0.004 and T-ALL
Table 1. IC50 (mM) regarding the effects of digitoxin and ouabain on primary leukaemic cells and PBMCs.
IC 50% T-ALL B-precursor ALL AML CLL PBMCs
Digitoxin Median (range) 0.07 (0.02–0.09) 0.06 (0.02–0.23) 0.12 (0.01–1) 0.28 (0.03–0.92) 0.44 (0.36–0.68)
Ouabain Median (range) 0.05 (0.004–0.08) 0.06 (0.05–0.34) 0.04 (0.03–10 *) 0.12 (0.06–0.28) 0.09 (0.03–0.19)
*Never reached IC 50%.
doi:10.1371/journal.pone.0015718.t001
Figure 2. Cytotoxic effects of digitoxin. A: Cytotoxic effects of
digitoxin (0.1 mM) expressed as Survival Index % (vs. untreated control
cells) in the various leukaemia types (T-ALL, B precursor ALL, AML and
CLL) and PBMC using the standard 72 h assay. B: Effects of
therapeutically achievable digitoxin concentrations against leukaemic
cells from patients and CCRF-CEM cell line over six days with daily
medium change.
doi:10.1371/journal.pone.0015718.g002
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more sensitive than the AML cells (p=0.02) (Figure 2A). With
extended exposure (6 days) both T- and B-precursor ALL cells
appeared sensitive at clinically achievable concentrations
(Figure 2B).
The cell line SUP-B15 was highly sensitive to all tested CGs,
with IC50 values as follows: digitoxin 0.002 mM, ouabain
0.004 mM and digoxin 0.03 mM. The T-lymphoblast-like cell line
CCRF-CEM showed effects similar to those in the primary ALL
cells, with IC50 values of 0.04 mM for ouabain, 0.12 mM for
digitoxin and 0.22 mM for digoxin. In both cell lines there was a
tendency towards a lower sensitivity to digoxin than to the other
two CGs.
Both digoxin and digitoxin inhibited DNA as well as protein
synthesis in CCRF-CEM and SUP-B15 cells. The effects of the
specific inhibitors aphidicolin and cycloheximide, used as positive
controls, were strong and immediate. As presented in Figure 3
(digitoxin only; digoxin showed similar results), the effects were,
however, only observed at relatively high concentrations, and at
100 nM, surprisingly, no significant effects were detected during
the 24-h observation period. At the highest concentration tested
(1.0 mM), well exceeding the IC50 value for cytotoxicity, the effects
on DNA and protein synthesis were similar in time and
magnitude, i.e. the cells tended to ‘‘shut down’’ in an expected
manner due to the toxic insult, presumably related to severe ionic
imbalance. To put these results into perspective, a comparator cell
line, the adenocarcinoma cell line Hct116was also analysed. As the
Hct116 cell line is more tolerant to the cytotoxic effects of
glycosides, slightly higher CG concentrations were used. Figure 4
shows the effects of various digitoxin concentrations on DNA (A)
and protein synthesis (B). In contrast to the results in the leukaemia
cell lines, protein synthesis in Hct116 cells was decreased more
efficiently (i.e. at concentrations corresponding to cytotoxic
activity) and at an earlier time point than DNA synthesis. With
1 mM digitoxin, protein synthesis in Hct116 cells was effectively
inhibited at early time points (significant from 6 hours), while
DNA synthesis did not appear to slow down until 24 h. This
concentration is comparable to the cytotoxic IC50 value for
Hct116 cells measured in the FMCA (0.71 mM, Figure 4C). The
effects in two other colorectal adenocarcinoma cell lines (HT29
and CC20) were similar (not shown). The leukaemic SUP-B15 cell
line was approximately 500 times more sensitive to the cytotoxic
effects of digitoxin, with an IC50 value of 1.5 nM (Figure 4C).
Despite this, exposure of SUP-B15 cells to 10 nM digitoxin had no
effect on protein synthesis up to 24 h (Figures 3D and 4D), but it
effectively reduced viability at 72 h (Figure 4D). Results in the
leukaemic CCRF-CEM cell line were similar (not shown).
Discussion
In this study we have identified primary B-precursor and T-
ALL cells as being particularly susceptible to the cytotoxic effects
of CGs, being significantly more sensitive than CLL cells and
PBMCs. Digitoxin was the most potent of the CGs tested, and the
measured IC50 value was comparable with therapeutic serum
concentrations, especially if exposure time was extended to 6 days.
The therapeutic concentration range for CGs in clinical use is
narrow – for digitoxin 15–40 nmol/l (10–30 ng/ml) [27]. This, of
Figure 3. Effects of digitoxin on DNA synthesis in leukaemic cell lines. Effects of digitoxin exposure on DNA synthesis (i.e. thymidine
incorporation) in CCRF-CEM (A) and SUP-B15 (B) cells. The DNA polymerase inhibitor aphidicolin (15 mM) was used as a positive control. Effects of
digitoxin exposure on protein synthesis (i.e. leucine incorporation) in CCRF-CEM (C) and SUP-B15 (D) cells. The ribosomal inhibitor cycloheximide
(36 mM) was used as a positive control.
doi:10.1371/journal.pone.0015718.g003
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for CGs in the treatment of acute leukaemia, despite negative
results in solid tumours, for example. In ALL maintenance
treatment with moderate doses of 6-mercaptopurin and metho-
trexate for a period of approximately two years has a documented
effect on the risk of relapse [28]. The intensity of the treatment is
limited by haematological and/or liver toxicity. New drugs with
different toxicity spectra could clearly be of substantial benefit in
this setting. Therefore, digitoxin as an addition to conventional
maintenance chemotherapy in ALL could be proposed as a future
clinical study, but only after careful preclinical investigation of
possible drug-drug interactions. For example, previous studies
have indicated that digitoxin at concentrations commonly found in
the plasma of cardiac patients, significantly reduced etoposide and
idarubicin-induced topoisomerase II cleavable complexes in K562
leukemia cells [29].
The cytotoxic effect of digitoxin on both primary ALL cells as
well as in the extremely sensitive cell line SUP-B15S indicates that
a mechanism of inducing cell death other than inhibition of
sodium- and potassium-activated adenosine triphosphatase (Na
+/
K
+ ATPase) may be possible. Numerous effects of cardiac
glycosides in cancer cell lines ultimately leading to apoptosis have
been demonstrated previously. Most of these effects are probably
mediated through the main target enzyme [30]. However,
interpretation of experiments involving established cell lines calls
for caution because of possible genetic drift and altered properties.
This is illustrated by the extreme sensitivity towards CGs in the cell
line SUP-B15, while results in the CEM cell line were similar to
those in the primary leukaemic cells.
Despite years of interest in these effects and numerous studies in
vitro and in animals, it has not yet been possible to utilize the anti-
cancer potential of CGs clinically. Several preclinical studies have
demonstrated these compounds to be involved in selective control
of human proliferation, which support the use of CGs to treat
malignancies [30,31]. Different glycosides with different profile
regarding cellular effects and cardiotoxicity have been developed,
and several clinical trials have been performed. For example,
UNBS-1450, a semisynthetic cardenolide, with good preclinical
activity against NSCLC has entered a phase I clinical trial in
Belgium [32]. A phase I trial of Anvirzel
TM, an aqueous extract
from Nerium Oleander, in patients with refractory solid tumors has
been reported [33]. Studies of the addition of digoxin to
Figure 4. Comparison between colorectal and leukaemic cell lines. For comparative purposes the effects of digitoxin on DNA and protein
synthesis (A and B respectively) were also monitored in the colorectal adenocarcinoma cell line Hct116. Figure 4C shows differences in cytotoxic
activity of digitoxin in the Hct116 cell line and the leukaemic cell lines (CCRF-CEM and SUP-B15) used in the present study. In Figure 4D the effects on
survival (at 72 h, measured by FMCA) and protein synthesis at 24 hours at digitoxin concentrations slightly exceeding the IC50 values in HT29 and
SUP-B15 cells are shown.
doi:10.1371/journal.pone.0015718.g004
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advanced malignant melanoma have also been initiated [34], the
study has not been finally reported.
There are several possible explanations for this slow progression
into clinical practise; one is of course the possibility of in vitro
biases, and/or species differences. For example, it has been
demonstrated that oleandrin activates MAPK and JNK and also
induces expression of FasL, leading to apoptosis in human, but not
in murine cells (28). This difference has also been detected at the
cellular membrane level, as oleandrin altered its fluidity, inhibiting
Na
+/K
+ ATPase activity, and increasing intracellular free Ca
2+
levels, followed by calcineurin activity only in human, but not in
murine cells. The results suggested that murine plasma mem-
branes might be different from human membranes, which interact
with oleandrin, disturbing the Na
+/K
+ ATPase pump and
resulting in calcification, followed by induction of Ca
2+-dependent
cellular responses such as apoptosis [35]. In line with these
findings, Perne et al. recently published experimental results
suggesting that general inhibition of protein synthesis is the main
mechanism of the anti-cancerous effects of CGs in human cells,
and that physiological species differences may explain the
previously observed sensitivity of human cancer cells in mouse
xenograft experiments [20]. It was proposed that inhibition of
protein synthesis is directly related to effects on the Na
+/K
+
ATPase pump. Indeed, this protein synthesis-inhibiting mecha-
nism is supported by observations in the colorectal adenocarcino-
ma cell line Hct116 (Figure 4). With 1 mM digitoxin, protein
synthesis is effectively inhibited at early time points (significant
from 6 hours), leading to decreased cell numbers at 72 hours. It
might be concluded that Hct116 cells die because of an inability to
synthesize vital proteins. The results from the leukaemia cell lines
appear to be in sharp contrast to this – protein synthesis levels at
time points up to 24 h are unaffected by concentrations having
severe effects on cellular viability. Thus, it may be concluded that
these cells stop synthesizing their proteins because they are dying,
rather than the opposite.
Conclusions
Cardiac glycosides have been used for treatment of congestive
heart failure and atrial fibrillation for over a century. During the
last twenty years this class of compounds (e.g. digitoxin and
oubain) has received much attention as regards their potential as
anti-cancer agents, based on epidemiological as well as experi-
mental findings. Despite great efforts the mechanism behind the
anti-cancerous effects has been difficult to determine, as have the
potential benefits in the clinic. The recently published study by
Perne et al. [20] shed some light on this issue, but also strongly
discouraged further clinical development of CGs, and derivatives
thereof, for use in this therapeutic area. In this study we describe
how some subsets of leukaemic cells from patients express high
sensitivity towards CGs, particularly digitoxin, and at concentra-
tions that may be achieved in the clinic. Furthermore, it was
shown that the suggested mechanism of protein inhibition is valid
in tumour cell lines with moderate or high resistance to the
cytotoxic effects of CGs, but probably not in highly sensitive
cancer cell lines. It is thus suggested that further investigation may
be focused on diagnoses like T- and B-precursor ALL.
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